St. Jude Expects To Take More CRT Share From Guidant Than Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Guidant's share of the cardiac resynchronization therapy (CRT) market is more vulnerable than that of Medtronic, according to St. Jude Medical CFO John Heinmiller